Navigation Links
Gene therapy reversed heart damage in heart failure
Date:12/29/2008

(PHILADELPHIA) Long-term gene therapy resulted in improved cardiac function and reversed deterioration of the heart in rats with heart failure, according to a recent study conducted by researchers at Thomas Jefferson University's Center for Translational Medicine. The study was published online in Circulation.

The rats were treated with a gene that generates a peptide called ARKct, which was administered to hearts in combination with recombinant-adeno-associated virus serotype 6 (rAAV6). ARKct works by inhibiting the activation of G protein-coupled receptor kinase 2 (GRK2).

GRK2 is a kinase that is increased in heart failure myocardium. Enhanced GRK enzymatic activity contributes to the deterioration of the heart in heart failure, according to Walter J. Koch, Ph.D., the W.W. Smith Professor of Medicine and the director of the Center for Translational Medicine at Jefferson Medical College of Thomas Jefferson University. Dr. Koch's research team carried out the study, which was led by Giuseppe Rengo, M.D., a post-doctoral fellow.

"The theory is that by inhibiting this kinase, the heart will recover partially due to reversal of the desensitization of the -adrenergic receptors," Dr. Koch said. "The expression of ARKct leads to a negative neurohormonal feedback that prevents the heart from continuing on the downward slope during heart failure. This was one novel finding of the study."

Dr. Koch and his colleagues used five groups of rats in their study. Two groups received rAAV6 with the ARKct peptide, two groups received rAAV6 with green fluorescent protein (GFP), and the last group received a saline treatment. One of the ARKct groups and one of the GFP groups also received the beta blocker metoprolol concurrently.

Twelve weeks after receiving the treatment, the rats who received the ARKct had a significantly increased left ventricular ejection fraction. The treatment also reversed the left ventricular deterioration and normalized the neurohormonal status. Dr. Koch said that targeting the GRK2 enzyme with ARKct was sufficient to reverse heart failure even without concomitant metoprolol.

The rats that received GFP or saline alone experienced more deterioration of cardiac function during the course of the study. This deterioration was prevented, but not reversed, with the concomitant metoprolol.

"Our data show that beta blockers and the ARKct peptide are compatible and can be given together," Dr. Koch said. "Although beta blockers are effective at stopping the downward progression of the disease, they do not reverse the damage already done. That is where the ARKct gene therapy comes in."

In future trials in humans, the ARKct peptide will be administered with beta blockers, which are the standard treatment. However, Dr. Koch said that if a pharmaceutical inhibitor can be developed, then a new class of drugs to treat heart failure could possibly even replace beta blockers.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related biology news :

1. Leeds research points to new therapy for hepatitis C treatment
2. UC Davis researchers exploring gene therapy to fight AIDS
3. Gene therapy corrects sickle cell disease in laboratory study
4. Medicare coding for maggots and maggot therapy
5. Scientist clears hurdles for muscular dystrophy therapy
6. Researchers at UH explore use of fat cells as heart attack therapy
7. How eating fruit and vegetables can improve cancer patients response to chemotherapy
8. Gene therapy restores vision to mice with retinal degeneration
9. Researchers identify promising gene target for neuroblastoma therapy
10. On the trail of a targeted therapy for blood cancers
11. Breast cancer cells recycle to escape death by hormonal therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, an ... Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to include allergy ... fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are escalating to ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced the release of Limfinity® version 6.5, a content-packed update to the Limfinity® ... to gain a larger and more diverse base of customers among labs and ...
(Date:6/20/2017)... 2017  Kibow Biotech Inc., a pioneer in developing ... of a new patent covering a unique method for ... Patent and Trademark Office on May 23 rd ... of Bio award in 2014 in San ... approaches to chronic disease. Renadyl™, the first and only ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., a clinical ... it is launching two new additions of its award-winning cloud-based platform CONFORM™: Information ... the DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern ...
Breaking Biology Technology: